Application of angiotensin converting enzyme inhibitor

An angiotensin-converting enzyme technology, applied in the field of biomedicine, to achieve the effects of enhancing insulin sensitivity, enhancing adaptability, and improving glucose tolerance

Inactive Publication Date: 2014-09-03
INST OF ZOOLOGY CHINESE ACAD OF SCI
3 Cites 1 Cited by

AI-Extracted Technical Summary

Problems solved by technology

There are no studies on the use of angiotensin-converting enzyme i...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Abstract

The invention provides an application of an angiotensin converting enzyme inhibitor, and in particular relates to the application of the angiotensin converting enzyme inhibitor in preparing medicine for treating obesity, obesity related diseases, improving energy metabolism or promoting heat generating. The experiment proves that the angiotensin converting enzyme inhibitor fosinopril treatment is capable of effectively inhibiting the obesity induced by high fat diet, treating insulin resistance induced by the high fat diet, improving the glucose tolerance dose of the organism by increasing the energy metabolism level of the organism, enhancing the insulin sensitivity of the tissue, and enhancing the adaptability of the organism to cold excitation by activating the organism to generate heat; and a new path for treating the obesity and related diseases is developed.

Application Domain

Technology Topic

Image

  • Application of angiotensin converting enzyme inhibitor
  • Application of angiotensin converting enzyme inhibitor
  • Application of angiotensin converting enzyme inhibitor

Examples

  • Experimental program(3)

Example Embodiment

[0034] Example 1 Fosinopril can inhibit obesity induced by high-fat diet
[0035] In order to verify the anti-obesity effect of ACE inhibitors, we prepared the following high-fat diet-induced obesity mouse model: 6-week-old C57BL/6J male mice were fed 60Kcal% high-fat diet (Research diet, D12451 ), record weight every week. After 8 weeks of induction and obesity, the high-fat diet induced obesity group was randomly divided into obese control group (HFD, 10) and obese fosinopril group (HFD+ACEI, 14); then obese fosinopril group , Treated with Fosinopril, administered at a dose of 134mg/10kg/day (equivalent to 1.34mg/kg body weight/day); the obese control group and the normal diet group (7 animals, LFD, fed 10Kcal% low Fat feed, Research diet, D12450B), treated with the same dose of starch, administered by mixing into the feed, and continuously administered. The average daily food intake of each experimental group of animals was measured in the first 2 weeks of administration, and the Record your weight every week. After 10 weeks of continuous administration, the mice were sacrificed by cervical dislocation, and the liver, epididymal fat and subcutaneous fat were taken out and weighed.
[0036] The result is Figure 2-4 As shown, figure 2 It shows that fosinopril treatment can effectively inhibit the obesity induced by high-fat diet, and this effect can appear from the first week of fosinopril treatment to the tenth week of the end of the experiment, the maximum difference in body weight, specifically obesity The control group was 46.02±2.5g, the obese fosinopril group was 40.45±3.9g, p <0.001.
[0037] image 3 It shows that compared with the obese control group, the weight percentage of body fat in the fosinopril treatment group decreased by about 13%.
[0038] Figure 4 Show that the treatment of fosinopril reduces the body’s fat deposits, especially significantly reduces the weight of liver and subcutaneous fat (p <0.01).

Example Embodiment

[0039] Example 2 Fosinopril can improve insulin resistance induced by high-fat diet
[0040] Many research results show that obesity is often accompanied by severe insulin resistance; for this reason, we took the mice at the 9th week of administration in Example 1, and conducted the following experiments:
[0041] 1. Intraperitoneal glucose tolerance test (intraperitoneal glucose tolerance test, IPGTT): the mice after 10 weeks of administration in Example 1 were fasted overnight, after weighing, intraperitoneal injection of glucose 1.5g/kg body weight, after injection, blood glucose The instrument measures blood glucose at 0min, 15min, 30min, 45min, 60min, 90min and 120min.
[0042] The result is Figure 5 As shown, the fasting blood glucose (8.51±1.46mM) of the obesity control group induced by the high-fat diet was significantly higher than that of the normal diet group (6.35±0.73mM), and the treatment of fosinopril can effectively restore the high-fat diet induction Hyperglycemia (6.83±0.98mM, p <0.05); and draw the area under the curve of the glucose tolerance test, the results are as follows Image 6 As shown, it indicates that Fosinopril can significantly improve the clearance of blood sugar (p <0.05).
[0043] 2. Insulin tolerance test (ITT): The mice after 10 weeks of administration in Example 1 were fasted for 6 hours, weighed and injected with insulin 1IU/kg body weight in the abdominal cavity. After the injection, use a blood glucose meter Blood glucose was measured at 0min, 5min, 30min, 45min, 60min, 90min and 120min respectively.
[0044] The result is Figure 7 This indicates that Fosinopril can significantly improve insulin sensitivity.
[0045] All in all, from Figure 5-7 As a result, it can be seen that Fosinopril can improve insulin resistance induced by a high-fat diet.

Example Embodiment

[0046] Example 3 Fosinopril can improve energy consumption
[0047] Take the mice after the 10th week of administration in Example 1, measure their oxygen consumption with LabMaster of TSE Company, and place them under the conditions of 25°C and 4°C to measure the body temperature of the mice.
[0048] The result is Figure 8-9 As shown, it can explain the effect of fosinopril on body weight and insulin sensitivity. by Figure 8 We can see that Fosinopril increases the body’s oxygen consumption, indicating that Fosinopril improves the body’s overall energy metabolism (p <0.05). Not only that, Picture 9 Shows that Fosinopril can effectively improve the fever under cold stimulation (p <0.05).
[0049] In summary, Figure 8-9 The results suggest that Fosinopril can increase the body's energy metabolism.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Similar technology patents

Medicine composition used for treating diabetes mellitus

InactiveCN108159268AImprove glucose toleranceIncrease insulin sensitivityOrganic active ingredientsMetabolism disorderMetforminDrug
Owner:王桂芬

Application of human Nectin-2 protein

ActiveCN104418951AIncrease energy metabolismImprove glucose toleranceFungiBacteriaDiseaseHyperlipidemia
Owner:BEIJING VDJBIO

Methods of Improving Glucose Tolerance, Hair Regrowth, and Bio-Availability

InactiveUS20170119693A1Improve glucose toleranceCosmetic preparationsHair cosmeticsResveratrolArginine binding
Owner:KOTHARI SHIL +1

Novel peptides and uses thereof in therapeutic methods

InactiveUS20140155324A1Promote sugar metabolismImprove glucose toleranceNervous disorderPeptide/protein ingredientsDrugPeptide
Owner:TWO TO BIOTECH

Classification and recommendation of technical efficacy words

  • Increase energy metabolism
  • Improve glucose tolerance

Application of human Nectin-2 protein

ActiveCN104418951AIncrease energy metabolismImprove glucose toleranceFungiBacteriaDiseaseHyperlipidemia
Owner:BEIJING VDJBIO

Special sea dietary food for diabetics

InactiveCN102077936AImprove glucose toleranceHigh sensitivityFood preparationSea foodActivity factor
Owner:广州蓝钥匙海洋生物工程有限公司

Compositions and methods for the treatment of liver diseases and disorders

PendingUS20190388377A1Improve glucose toleranceDecreasing and preventing liver injuryDipeptide ingredientsMetabolism disorderLiver diseaseLiver function
Owner:AXCELLA HEALTH INC

Compound dendrobium officinale health care product capable of assisting in reducing blood sugar

InactiveCN106344808ALower fasting blood sugarImprove glucose toleranceMetabolism disorderNatural extract food ingredientsDiabetic complicationPancreatic structure
Owner:ZHEJIANG TIANFANG TECH CO +2
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products